CD274 and breast cancer: Breast cancers with germline MMR variants showed relatively high rates of MMR protein loss, TMB-high and PD-L1 positive expression compared with general breast cancers, suggesting that some breast cancer patients with germline MMR variants might benefit from immunotherapy.